Oral immunotherapy (OIT) is a significant focus of treatment for egg and cow’s milk food allergy, inducing desensitization in the majority of individuals with these sensitivities (1,2). A major drawback of OIT is the frequency of adverse effects and although most are mild and self-limited the use of parenteral epinephrine is not infrequent. As many as 20-30% of food allergic patients are refractory to desensitization, particularly patients with higher initial food-specific IgE levels (3). To address some of the safety issues associated with OIT, anti-IgE monoclonal antibody (omalizumab) was proposed as an adjunct to facilitate OIT by reducing OIT-induced allergic reactions. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.